Clinical Trials Browser

Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT06083883 2026-04-16

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Phase 1 Recruiting

44 enrolled

Sarcoma

Sarcoma, Synovial, Liposarcoma, Myxoid

NCT04897321 2026-04-15

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Phase 1 Recruiting

48 enrolled

CNSDermatologicGastrointestinalGenitourinarySarcoma

Adrenal Cortex Neoplasms, Carcinoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Sarcoma, Clear Cell, Neurofibrosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT02306161 2026-04-13

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Phase 3 Active not recruiting

312 enrolled 14 charts

Sarcoma

Sarcoma, Ewing

NCT02567435 2026-04-13

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Phase 3 Active not recruiting

325 enrolled 14 charts

Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT07297667 2026-04-13

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Phase 1 Not yet recruiting

30 enrolled

BreastGenitourinarySarcoma

Carcinoma, Renal Cell, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

NCT04715191 2026-04-06

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Phase 1 Recruiting

24 enrolled

GastrointestinalGenitourinarySarcoma

Liposarcoma, Liver Neoplasms, Wilms Tumor, Rhabdomyosarcoma, Endodermal Sinus Tumor, Rhabdoid Tumor

NCT03721068 2026-03-27

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

Phase 1 Recruiting

18 enrolled

CNSSarcoma

Gaucher Disease, Neuroblastoma, Osteosarcoma

NCT03420963 2026-03-20

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Phase 1 Terminated

12 enrolled

DermatologicGenitourinaryHead & NeckOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Bone Neoplasms, Endocrine Gland Neoplasms, Melanoma, Mouth Neoplasms, Pharyngeal Neoplasms, Sarcoma, Skin Neoplasms, Thyroid Neoplasms, Urologic Neoplasms

NCT06865664 2026-03-16

FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma

Phase 1 Recruiting

50 enrolled

Sarcoma

Rhabdomyosarcoma, Sarcoma

NCT07194044 2026-03-16

METTSEO

Phase 1 Recruiting

15 enrolled

Sarcoma

Sarcoma, Ewing

NCT01046487 2026-03-13

PALANGI3

Phase 1 Completed

26 enrolled

DermatologicGastrointestinalSarcoma

Uveal Melanoma, Chordoma, Carcinoma, Adenoid Cystic, Neoplasms, Desmoid Tumors, Dermatofibrosarcoma, Gastrointestinal Stromal Tumors

NCT01804634 2026-03-13

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Phase 2 Recruiting

60 enrolled

CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

132 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07466316 2026-03-12

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

Phase 3 Not yet recruiting

342 enrolled

Sarcoma

Rhabdomyosarcoma

NCT02574728 2026-03-02

AflacST1502

Phase 2 Active not recruiting

46 enrolled

CNSMyeloidSarcoma

Brain Neoplasms, Carcinoma, Ependymoma, Histiocytosis, Langerhans-Cell, Medulloblastoma, Neoplasms, Neoplasms, Germ Cell and Embryonal, Neuroblastoma, Pinealoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

NCT06474676 2026-02-27

T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

Phase 1 Recruiting

40 enrolled

Sarcoma

NCT05304585 2026-02-24

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Phase 3 Recruiting

205 enrolled

Sarcoma

Rhabdomyosarcoma, Embryonal

NCT07428993 2026-02-24

Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma

Phase 2 Not yet recruiting

41 enrolled

Sarcoma

Osteosarcoma

NCT04052334 2026-02-20

Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

Phase 1 Completed

9 enrolled 10 charts

Sarcoma

NCT07174427 2026-02-18

Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma

Phase 3 Recruiting

5 enrolled

Sarcoma

Sarcoma, Synovial

NCT04994132 2026-02-17

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Phase 3 Active not recruiting

118 enrolled

Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT06820957 2026-02-17

Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body

Phase 2/3 Active not recruiting

437 enrolled

Sarcoma

Sarcoma, Ewing

NCT07227571 2026-02-11

Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial

Phase 1 Recruiting

30 enrolled

Sarcoma

Osteosarcoma

NCT07222735 2026-02-09

Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas

Phase 1 Recruiting

42 enrolled

Sarcoma

Sarcoma, Sarcoma, Ewing

NCT00902044 2026-01-26

HEROS

Phase 1 Active not recruiting

36 enrolled

Sarcoma

NCT01231906 2026-01-23

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Phase 3 Completed

642 enrolled 11 charts

Sarcoma

Localized Extraskeletal Ewing Sarcoma

NCT01953900 2026-01-23

VEGAS

Phase 1 Active not recruiting

26 enrolled

CNSSarcoma

Chickenpox, Neuroblastoma, Osteosarcoma

Clinical Trials

IGNYTE-ESO

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma

METTSEO

PALANGI3

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

PNeoVCA

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

AflacST1502

T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma

Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body

Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial

Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas

HEROS

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

VEGAS